S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Conditions

• Extensive Stage Lung Small Cell Carcinoma
• Limited Stage Lung Small Cell Carcinoma
• Lung Small Cell Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Magnetic Resonance Imaging — PROCEDURE
  Undergo MRI
• Prophylactic Cranial Irradiation — RADIATION
  Undergo PCI

Study Details

This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

Key Dates

Start date

May 4, 2020

Status verified

Jun 2026

Primary completion

Mar 17, 2026

Completion

Nov 15, 2029

Study Design

Enrollment

668 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Arm I (PCI, MRI)
  Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
• Experimental: Arm II (MRI)
  Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.

Primary Outcome Measure

Overall survival (OS) [ Time Frame: From the date of registration to date of death due to any cause, assessed up to 2 years after randomization ]

Locations (428)

Find similar trials in Birmingham, AL

Related Studies

• Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
  PHASE2/PHASE3 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
  PHASE2 · Recruiting · Roswell Park Cancer Institute · Buffalo, New York
• Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
  PHASE2 · Recruiting · Dwight Owen · Chicago, Illinois
• Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
  PHASE1 · Recruiting · Emory University · Atlanta, Georgia